Published in Arch Neurol on January 01, 1974
Water manganese exposure and children's intellectual function in Araihazar, Bangladesh. Environ Health Perspect (2006) 3.42
Arsenic and manganese exposure and children's intellectual function. Neurotoxicology (2011) 1.82
Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx (2004) 1.77
Manganese and Parkinson's disease: a critical review and new findings. Environ Health Perspect (2010) 1.66
The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A (2004) 1.59
Manganese and its role in Parkinson's disease: from transport to neuropathology. Neuromolecular Med (2009) 1.54
Differential cytotoxicity of Mn(II) and Mn(III): special reference to mitochondrial [Fe-S] containing enzymes. Toxicol Appl Pharmacol (2001) 1.35
Cancer incidence among workers in the Norwegian ferroalloy industry. Br J Ind Med (1986) 1.26
Concentrations and potential health risks of metals in lip products. Environ Health Perspect (2013) 1.24
Possibilities of detecting health effects by studies of populations exposed to chemicals from waste disposal sites. Environ Health Perspect (1985) 1.17
Arsenic exposure and motor function among children in Bangladesh. Environ Health Perspect (2011) 1.15
Time to re-evaluate the guideline value for manganese in drinking water? Environ Health Perspect (2007) 1.10
Chelation therapy of manganese intoxication with para-aminosalicylic acid (PAS) in Sprague-Dawley rats. Neurotoxicology (2008) 1.09
Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci (2015) 1.07
Manganese neurotoxicity: new perspectives from behavioral, neuroimaging, and neuropathological studies in humans and non-human primates. Front Aging Neurosci (2013) 1.04
Acquired hepatocerebral degeneration. J Neurol (2009) 0.98
Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. J Neural Transm (Vienna) (2006) 0.89
HPLC analysis of para-aminosalicylic acid and its metabolite in plasma, cerebrospinal fluid and brain tissues. J Pharm Biomed Anal (2010) 0.87
Associations of welding and manganese exposure with Parkinson disease: review and meta-analysis. Neurology (2012) 0.87
Manganese-Induced Parkinsonism and Parkinson's Disease: Shared and Distinguishable Features. Int J Environ Res Public Health (2015) 0.86
Manganism in the 21st century: the Hanninen lecture. Neurotoxicology (2013) 0.83
Methylcyclopentadienyl manganese tricarbonyl: health risk uncertainties and research directions. Environ Health Perspect (1998) 0.83
Rat brain endothelial cells are a target of manganese toxicity. Brain Res (2010) 0.82
Manganese intoxication. West J Med (1975) 0.80
Dimercaptosuccinic acid (DMSA): negligible effect on manganese in urine and blood. Occup Environ Med (1995) 0.80
Brain regional pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite: effectiveness in chelating brain manganese. Drug Metab Dispos (2011) 0.79
Roles of P-glycoprotein and multidrug resistance protein in transporting para-aminosalicylic acid and its N-acetylated metabolite in mice brain. Acta Pharmacol Sin (2014) 0.77
Environmental effects on the central nervous system. Environ Health Perspect (1977) 0.76
Neuropathology of heavy metal intoxication. Environ Health Perspect (1978) 0.76
Manganese inhalation as a Parkinson disease model. Parkinsons Dis (2010) 0.75
Cell-Penetrating Fragments of the Cdk5 Regulatory Subunit Are Protective in Models of Neurodegeneration. Pharmaceuticals (Basel) (2010) 0.75
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Using patient and general practice characteristics to explain variations in cervical smear uptake rates. BMJ (1994) 9.81
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (1999) 6.03
British Regional Heart Study: geographic variations in cardiovascular mortality, and the role of water quality. Br Med J (1980) 5.56
Core assessment program for intracerebral transplantations (CAPIT). Mov Disord (1992) 5.51
Prevalence of ischaemic heart disease in middle aged British men. Br Heart J (1984) 5.41
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet (1997) 5.39
Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet (1995) 5.11
Social class differences in ischaemic heart disease in British men. Lancet (1987) 4.09
Using data from the 1991 census. BMJ (1995) 3.63
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
Huntington disease: clinical care and evaluation. Neurology (1979) 3.54
Home visiting by general practitioners in England and Wales. BMJ (1996) 3.31
Health effects of passive smoking. 6. Parental smoking and childhood asthma: longitudinal and case-control studies. Thorax (1998) 3.19
Delayed-onset dystonia in patients with "static" encephalopathy. J Neurol Neurosurg Psychiatry (1980) 3.19
Cardiovascular risk factors in British children from towns with widely differing adult cardiovascular mortality. BMJ (1996) 3.14
Loss of employment and mortality. BMJ (1994) 3.06
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02
The Washington Heights-Inwood Genetic Study of Essential Tremor: methodologic issues in essential-tremor research. Neuroepidemiology (1997) 2.96
Health of unemployed middle-aged men in Great Britain. Lancet (1982) 2.94
Early influences on blood pressure: a study of children aged 5-7 years. BMJ (1989) 2.90
Sociodemographic variables for general practices: use of census data. BMJ (1995) 2.90
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol (1996) 2.86
Performance of a new pubertal self-assessment questionnaire: a preliminary study. Paediatr Perinat Epidemiol (2001) 2.85
Reliability of eliciting physical signs in examination of the chest. Lancet (1988) 2.71
Prevalence, detection, and management of cardiovascular risk factors in different ethnic groups in south London. Heart (1997) 2.65
Recall of diagnosis by men with ischaemic heart disease. Br Heart J (1984) 2.57
Explaining variation in hospital admission rates between general practices: cross sectional study. BMJ (1999) 2.56
Blood pressure in British children: associations with adult blood pressure and cardiovascular mortality. Lancet (1988) 2.51
Size at birth and blood pressure: cross sectional study in 8-11 year old children. BMJ (1997) 2.45
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology (2007) 2.41
The DYT1 phenotype and guidelines for diagnostic testing. Neurology (2000) 2.39
Health effects of passive smoking. 1. Parental smoking and lower respiratory illness in infancy and early childhood. Thorax (1997) 2.36
Children's exposure to passive smoking in England since the 1980s: cotinine evidence from population surveys. BMJ (2000) 2.28
Regression of area mortality rates on explanatory variables: what weighting is appropriate? J R Stat Soc Ser C Appl Stat (1981) 2.26
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology (2006) 2.25
Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart (2005) 2.24
Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection. Lancet (1989) 2.23
Idiopathic cervical dystonia: clinical characteristics. Mov Disord (1991) 2.21
Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart (2003) 2.20
Giving up smoking and the risk of heart attacks. A report from The British Regional Heart Study. Lancet (1986) 2.19
Accuracy of family history data on Parkinson's disease. Neurology (2003) 2.15
Functional brain networks in DYT1 dystonia. Ann Neurol (1998) 2.14
Oral and genital tardive pain syndromes. Neurology (1994) 2.07
What factors are associated with physical activity in older people, assessed objectively by accelerometry? Br J Sports Med (2008) 2.07
Is body mass index before middle age related to coronary heart disease risk in later life? Evidence from observational studies. Int J Obes (Lond) (2009) 2.05
What is it? Case 3, 1991: moaning in a man with parkinsonian signs. Mov Disord (1991) 2.05
Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord (1995) 2.03
Distant effects of local injection of botulinum toxin. Muscle Nerve (1987) 2.02
Motor blocks in Parkinson's disease. Neurology (1992) 2.01
Is the clinical trial evidence about new drugs statistically adequate? Br J Clin Pharmacol (1985) 2.01
Idiopathic dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann Neurol (1989) 2.00
Chronic exposure to outdoor air pollution and lung function in adults. Thorax (2009) 1.98
Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart (2002) 1.98
Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology (1994) 1.97
Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc Natl Acad Sci U S A (1993) 1.96
A critical review of the effect of factory closures on health. Br J Ind Med (1991) 1.95
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord (1987) 1.92
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology (1982) 1.88
Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord (1994) 1.88
Trends in secondary prevention of ischaemic heart disease in the UK 1994 2005: use of individual and combination treatment. Heart (2007) 1.87
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. I. An associated sodium-activated transphosphorylation. J Biol Chem (1966) 1.86
Age of menarche in contemporary British teenagers: survey of girls born between 1982 and 1986. BMJ (2001) 1.81
Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci (1992) 1.79
Linkage mapping of dopa-responsive dystonia (DRD) to chromosome 14q. Nat Genet (1993) 1.78
Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve (1991) 1.77
Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology (1990) 1.77
The Dinamap 1846SX automated blood pressure recorder: comparison with the Hawksley random zero sphygmomanometer under field conditions. J Epidemiol Community Health (1992) 1.77
ABO blood group and ischaemic heart disease in British men. BMJ (1990) 1.76
The effects of adiposity and weight change on forced expiratory volume decline in a longitudinal study of adults. Int J Obes Relat Metab Disord (1999) 1.72
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol (1988) 1.72
Non-employment and changes in smoking, drinking, and body weight. BMJ (1992) 1.68
Selegiline and mortality in Parkinson's disease. Ann Neurol (1996) 1.67
Do maternal and intrauterine factors influence blood pressure in childhood? Arch Dis Child (1992) 1.66
Delayed-onset cerebellar syndrome. Arch Neurol (1996) 1.65
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. II. Effects of N-ethylmaleimide and other sulfhydryl reagents. J Biol Chem (1966) 1.62
Health and social precursors of unemployment in young men in Great Britain. J Epidemiol Community Health (1996) 1.60
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology (1998) 1.60
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology (2010) 1.57
Passive smoking and sudden infant death syndrome: review of the epidemiological evidence. Thorax (1997) 1.55
Time trends in respiratory symptoms in childhood over a 24 year period. Arch Dis Child (1993) 1.55
Flow-mediated dilation in 9- to 11-year-old children: the influence of intrauterine and childhood factors. Circulation (1997) 1.54
Cholesterol and arterial distensibility in the first decade of life: a population-based study. Circulation (2000) 1.53
Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab (1993) 1.52
High dosage anticholinergic therapy in dystonia. Neurology (1983) 1.52
Infections presenting for clinical care in early life and later risk of hay fever in two UK birth cohorts. Allergy (2008) 1.52
Outcome of selective ramisectomy for botulinum toxin resistant torticollis. J Neurol Neurosurg Psychiatry (1998) 1.52
Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol (1995) 1.51
Laserlight cues for gait freezing in Parkinson's disease: an open-label study. Parkinsonism Relat Disord (2010) 1.51
Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain (1998) 1.50
Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgrad Med J (1986) 1.49
Delayed-onset dystonia due to perinatal or early childhood asphyxia. Neurology (1991) 1.46
Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology (1981) 1.46
Socio-economic determinants of casualty and NHS Direct use. J Public Health (Oxf) (2008) 1.46